Details of the Drug

General Information of Drug (ID: DMCWLHD)

Drug Name

Upifitamab rilsodotin

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody drug conjugate

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium/phosphate cotransporter 2B (SLC34A2)	TTQPZTM	NPT2B_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05329545) A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT). U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Mersana Therapeutics